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Abstract
Objective: The objective of this study was to evaluate the anti-tumor effects of Ad/gTRAIL (an adenoviral vector in
which expression of GFP and TRAIL is driven by a human telomerase reverse transcriptase promoter, hTERT) on
malignant meningiomas and gliomas.
Background: Gliomas and meningiomas are the two most common types of human brain tumors. Currently there
is no effective cure for recurrent malignant meningiomas or for gliomas. Ad/gTRAIL has been shown to be
effective in killing selected lung, colon and breast cancer cells, but there have been no studies reporting its
antitumor effects on malignant meningiomas. Therefore, we tested the antitumor effect of Ad/gTRAIL for the first
time in human malignant meningioma and glioma cell lines, and in intracranial M6 and U87 xenografts.
Methods: Materials and Methods: Human malignant meningioma and glioma cells were infected with adenoviruses,
Ad/gTRAIL and Ad/CMV-GFP. Cell viability was determined by proliferation assay. FACS analysis and quantification of
TRAIL were used to measure apoptosis in these cells. We injected Ad/gTRAIL viruses in intracranial M6 and U87
xenografts, and measured the brain tumor volume, quantified apoptosis by TUNEL assay in the brain tumor tissue.
Results: Our studies demonstrate that in vitro/in vivo treatment with Ad/gTRAIL virus resulted in significant
increase of TRAIL activity, and elicited a greater tumor cell apoptosis in malignant brain tumor cells as compared to
treatment with the control, Ad/CMV-GFP virus without TRAIL activity.
Conclusions: We showed for the first time that adenovirus Ad/gTRAIL had significant antitumor effects against
high grade malignant meningiomas as well as gliomas. Although more work needs to be done, our data suggests
that Ad/gTRAIL has the potential to be useful as a tool against malignant brain tumors.
Background
Gliomas and meningiomas are the two most common
types of human brain tumors. Malignant gliomas are the
most aggressive and deadliest type of brain tumor[1].
Meningiomas, on the other hand, are usually benign but
often recur after surgical removal. They can undergo
malignant transformation, and depending on their loca-
tion can be serious and even potentially lethal to patients
[2]. It has been reported that there has been a steady
increase in the incidence of malignant brain tumors in
both adults and children [3]. There is no effective long-
term treatment for this disease. Cellular and molecular
therapies including novel vector based gene therapy are
currently being studied in preclinical and clinical settings
for intracranial malignancies [4-6].
Telomerase is the cellular enzyme responsible for the
replication of chromosomal ends or telomeres. It is a
multiunit ribonucleoprotein complex that contains an
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(hTR) and essential protein components including the
rate-limiting catalytic subunit human telomerase reverse
transcriptase (hTERT). The strong link between telomer-
ase activity and cancer was initially reported by Kim et al
[7]. Using a highly sensitive PCR based telemetric repeat
amplification protocol (TRAP) assay, they detected telo-
merase activity in many advanced tumors but not in nor-
mal somatic tissues or benign tumors. Since then, all
major types of cancer have been screened for telomerase
activity. It has been estimated that more than 85% of
human cancers have high telomerase activity, which
makes telomerase the most common tumor marker. Not
only has telomerase been proposed as a diagnostic and
prognostic marker for cancer, telomerase inhibition has
been widely tested as a potential anticancer strategy [8].
In addition, the high tumor-specificity of hTERT gene
expression and the fact that hTERT expression is mainly
regulated at the transcriptional level have prompted the
u s eo fa nh T E R Tp r o m o t e rt od r i v es u i c i d eg e n e st o
induce specific cancer cell killing using liposome or ade-
novirus delivery systems [9].
TRAIL, a member of the TNF family, triggers apoptosis
through interactions with death receptors (DR4 and DR5)
on the cell surface. We and others have shown that direct
transfer of the full-length coding sequence of the human
tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) into cancer cells elicited apoptosis and apoptotic
bystander effects on malignant cells and suppressed tumor
growth in vivo. More recently, we constructed a bicistronic
adenoviral vector expressing the GFP-TRAIL fusion pro-
tein from the hTERT promoter via GAL4 gene regulatory
system (Ad/gTRAIL) and demonstrated that Ad/gTRAIL
treatment effectively elicited apoptosis in various tumor
cells in vitro and suppressed xenograft tumor growth
in vivo, with no detectable toxicity in human primary
hepatocytes [10]. Since the hTERT promoter is tumor spe-
cific, expressing the TRAIL gene by hTERT could over-
come the possible liver toxicity reported for TRAIL gene
expression.
In this report, we determined the expression level of
hTERT in benign and malignant meningioma and glioma
cells and investigated the expression and efficacy of Ad/
gTRAIL in these cells. Our data showed that Ad/gTRAIL
is effective against highly malignant meningioma and glio-
mas without toxicity to normal cells in the brain and sug-
gest that Ad/gTRAIL may have potential usage in
malignant brain tumor therapy.
Results and Discussion
hTERT expression level in primary cultured meninglioma
cells and glioma cell lines
In general, hTERT expression levels correlate with the
degree of malignancy in cancer cells. We evaluated the
hTERT mRNA expression in primary cultured menin-
gioma cells and glioma cell lines using real-time RT
Q-PCR technique. As shown in (Figure 1A), very low
levels of hTERT expression were detected in three benign
meningioma cells (M43, M2, and M66) while higher level
hTERT was noted in M6 malignant meningioma cells.
All 3 higher grade glioma cell lines (U251, U87, and
U373) had significantly elevated hTERT expression.
However, NG-1 cells, derived from surgical specimens of
human gliomas (established in the Department of Neuro-
Oncology at The University of Texas M. D. Anderson
Cancer Center) showed a lower expression of hTERT
[11]. The low grade SW1088 glioma cell line also demon-
strated decreased hTERT levels [12]. These results con-
firmed that hTERT mRNA expression correlates with the
malignancy level of brain tumor cells.
Correlation between GFP-TRAIL expression and hTERT
level
hTERT is over expressed in up to 90% of cancer cells
[13,14]. Moreover, Ad/gTRAIL has been shown to be
selectively active in cancer cells. To test the effect of Ad/
gTRAIL on malignant brain tumors, we treated menin-
gioma cells (benign: M43, M2, M66; malignant: M6) and
glioma cells (NG-1, SW1088, U251, U87) with Ad/
gTRAIL or Ad/CMV-GFP. Cells treated with PBS were
used as a control. Cells were harvested 48 hr after virus
treatment, and then divided into two parts. One part was
used for GFP expression detection, and another part was
used for apoptosis analysis. As shown in (Figure 2A),
benign meningioma cells (M43, M2, M66) treated with
Ad/gTRAIL resulted in similar lower levels of GFP-posi-
tive cells (7.94%, 12.65% and 6.25% respectively), suggest-
ing that hTERT promoter activity was minimal in these
cells. On the other hand, Ad/gTRAIL infected M6 malig-
nant meningioma cells demonstrated significantly higher
GFP-positive cells (82.08%), reflecting increased hTERT
promoter activity. Similarly, the two highly malignant
glioma cell lines (U251 and U87) also had a high percen-
tage of GFP-positive cells (73.1% and 84.5% respectively),
indicating high hTERT promoter activity (Figure 2B). The
cells lines with intermediate hTERT expression (NG-1 and
SW1088) showed 36.4% and 47.4% GFP-positive cells
respectively (Figure 2B). Cells with PBS treatment have no
significant GFP-positive cells detected. There was no sig-
nificant difference in GFP-positive cells among different
group of cells treated with control vector Ad/CMV-GFP.
Targeting TRAIL induced apoptosis in malignant cells by
Ad/gTRAIL
Treatment of benign meningioma cells (M43, M2, M66)
with Ad/gTRAIL did not change the apoptosis rate when
compared to cells treated with control vector Ad/CMV-
GFP, indicating lack of hTERT-targeted mechanism.
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Figure 1 Endogenous hTERT activity and cell killing effect of Ad/gTRAIL: (A) Endogenous hTERT mRNA level in meningioma and glioma
cells. The hTERT mRNA level in primary cultured meningioma cells and glioma cell lines was determined by real time quantitative PCR as
described the Methods. The levels of b-actin was used as endogenous controls. (B) In vitro cell-killing effect of Ad/TRAIL on various brain tumor
cells. (B-1) Meningioma cells (B-2) Glioma cells. Cell viability was determined by XTT assay. Cells treated with PBS were used as a control, and
their viability was set at 1. Values are mean ± SD for two quadruplicate assays PBS (mock control), Ad/CMV-GFP (vector control), and M43, M2,
M66, M6 and NG-1 SW1088, U251, U87, Ad/gTRAIL., Cells were treated with MOI of 1000 VPs/ cell at 7 consecutive days. Cell viabiligy of M6,
U251, and U87 cells treated with Ad/gTRAIL was significantly different (p< 0.001) from that of Ad/CMV-GFP and PBS treated cells.
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Figure 2 Expression of GFP-TRAIL in brain tumor cells: (A) Meningioma cells and (B) Glioma cells. The GFP-TRAIL expression after treatment
with Ad/gTRAIL was determined by flow cytometric analysis. Cells treated with PBS or Ad/CMV-GFP was used as negative or positive control. On
the left side, cell lines; at the top, treatments; and percentages of cells expressing GFP are shown in each panel.
Li et al. Cancer Cell International 2011, 11:35
http://www.cancerci.com/content/11/1/35
Page 4 of 14However, malignant meningioma M6 cells treated with
Ad/gTRAIL showed 24% apoptosis rate, which is 4-fold
higher than cells treated with control Ad/CMV-GFP
(Figure 3A). In addition, Ad/gTRAIL induced significant
apoptosis (58% and 30.6%) in highly malignant U251 and
U87 cells respectively (Figure 3B). The percentages of
apoptosis for intermediate level hTERT expressing cell
lines are: NG-1, 13.9% and SW1088, 18.4% (Figure 3B).
Cells with PBS treatment have no effect on apoptosis
induction. It is noteworthy that control vector Ad/CMV-
GFP did not induce additional apoptosis as to PBS treated
groups.
Cytopathic effect of Ad/gTRAIL on human brain tumor
cells
To determine whether the infection of human brain tumor
cells with either Ad/gTRAIL or Ad/CMV-GFP would have
a cytopathic effect, we performed dose-dependence assays
with low-hTERT benign meningioma M66 cell, and high-
hTERT glioma U87 cell. The cells were seeded at 1 × 10
4
cells/well in flat-bottom 12-well plates. After an overnight
incubation, cells were divided into 3 groups and treated
with PBS, Ad/CMV-GFP, Ad/g-TRAIL respectively. The
treatment concentration of Ad/CMV-GFP, Ad/g TRAIL
were at MOIs of 500, 1000 and 3000 VPs/ cell. Benign
meningioma cells were evenly infected by the control vec-
tor Ad/CMV-GFP, showing strong green fluorescence
(Figure 4A).
However, due to selective expression of GFP-TRAI,
green fluorescence was observed only in malignant cells
(Figure 4F), and not in benign cells, (Figure 4B). This
suggests that after Adv/g TRAIL infection, differential
expression of the adenoviral transgene is mediated by the
tumor-selective promoter system and not influenced by
cellular susceptibility to virus infection. As shown in (Fig-
ure 4C & 4D), no obvious morphologic changes were
observed up to 5 days after all the treatments, suggesting
that even at an MOI of 3000 VPs/cell, Ad/gTRAIL is not
toxic to, and has no cytopathic effect on benign menin-
gioma cells. In comparison, obvious apoptotic morpholo-
gic changes were observed in the maligant glioma cells
after treatment with Ad/gTRAIL at an MOI of 1000 VPs/
cell (Figure 4F &4H). This result was consistent with our
previous observation that transgene expression from the
hTERT promoter after adenovector-mediated gene deliv-
ery is high in malignant cells but minimal in normal cells
[10,15]. This result also demonstrated that hTERT promo-
ter activity was in different levels in different grade brain
tumor cells.
Anti-proliferation effect of Ad/gTRAIL on human brain
tumor cells
To obtain further evidence that the hTERT promoter can
drive tumor specific expression of the TRAIL gene in
different grade menigioma and glioma cells, we used the
XTT assay to compare cell viability after treatment with
Ad/gTRAIL in all meningioma (Figure 1.B-1) and glioma
cells (Figure 1.B-2). The cell viability was significantly
lower in Ad/gTRAIL treatedU251, U87-glioma cells (p<
0.001), and M6 malignant meningioma cells (p<0.001)
when compared to the control Ad/CMV-GFP and PBS
treated. The increased cell death in U87 and U251
glioma, and M6 malignant meningioma cells was directly
correlated with hTERT expression level (Figure 3).
Apoptosis pathway elicited by Ad/gTRAIL in human brain
tumor cells
The induction of apoptosis by Ad/gTRAIL was confirmed
by western blot analysis (Figure 5). The TRAIL expression
was observed in cells treated with1000 MOI Ad/CMV-
GFP at 3 days (A),. and treated with 1000 MOI Ad/gTRAI
at 3 days (B). However, there was an increased expression
of TRAIL in meninglioma M6 and glioma U251 and U87
cells treated with Ad/gTRAIL when compared to benign
cells. Additionally, our data demonstrated that Ad/
gTRAIL was more effective in causing cell death and
apoptosis induction in malignant human brain tumor
cells, but not in benign tumor cells. This result suggests
that apoptosis is involved in cell death produced by the
TRAIL gene therapy.
Therapeutic effect of Ad/gTRAIL in intracranial
xenografted M6 and U87
To evaluate the therapeutic effect of Ad/gTRAIL in brain
tumors in vivo, we measured the anti-tumor growth effi-
cacy of Ad/gTRAIL in intracranial xenografted M6 menin-
g i o m aa n dU 8 7g l i o m a ,a n dc o m p a r e di tw i t ht h a to f
control vector Ad/CMV-GFP, and. In four independent
experiments, the mean survival for the control mice (mice
receiving Ad/CMV-GFP) was 19 days (95% CI = 14 to 24)
in meningioma, and 22 days (95% CI = 15 to 30 days) in
glioma respectively. In contrast, the survival for the Ad/
gTRAIL treated mice was 61 days (95% CI = 50 to 69
days) in meningioma, and 63 days (95% CI = 52 to 71
days) in glioma which was statistically significantly longer
than the mean survival of the control mice (p< 0,05; log-
rank test), (Figure 6A).
Histopatholgic Examination of Tumor in Brain
Microscopic examination of the brain of control mice with
M6 meningioma xenografts revealed non-infiltrative
tumor growing in a spherical pattern (Figure 6B1). Histo-
logical characteristics of the tumors included a dense cel-
lular mass, and the tumor center had necrotic areas
(Figure 6-B2 Arrow). All the brains of M6 and U-87 xeno-
grafted mice that died naturally showed a midline shift
and ventricular compression secondary to tumor-mass
effects, which are characteristic features of herniation, and
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Figure 3 Induction of apoptosis by Ad/gTRAIL: (A) Meningioma cells and (B) glioma cells were treated with PBS, Ad/CMV-GFP or Ad/gTRAIL
at MOI of 1000 VPs/ cell. Apoptosis were determined by flow cytometric assay at 4 days after the treatment. On the left side, the name of cell
lines; at the top, treatments; and percentages of apoptosis are shown.
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Figure 4 In vitro gene expression and cell killing: (A - D) Meninglioma cells (M66) treated with Ad/CMV-GFP (A, C) or Ad/gTRAIL (B, D).
Benign meningioma cells were treated with Ad/CMV-GFP or Ad/gTRAIL at 1000 MOI Expression of GFP or its fusion protein was revealed under
a fluorescent microscope at 5 days after the treatment. (E-H) Glioma cells (U87) treated with Ad/CMV-GFP (E, G) or Ad/gTRAIL (F, H). Malignant
Glioma cells treated with Ad/CMV-GFP or Ad/gTRAIL as described for meninglioma cells. Expressions of GFP or its fusion protein (A, B, E, F) were
revealed under a fluorescent microscope. The cells morphologies (C, D, G, H) were revealed under regular microscope. Note, glioma cells treated
with Ad/gTRAIL showed apoptosis morphology with the membrane blebbing and cell shrinkage and apoptosis.
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Page 7 of 14indicate that growth was probably the cause of death in
mice that died naturally.
Immunohistochemical staining for TUNEL assay
To assess apoptosis induction in vivo, we performed term-
inal deoxynucleotidyl transferase-mediated dUTP labeling
(TUNEL) staining on tumor sections in 2 treatment
groups. Brown color indicates apoptotic nuclei as visualized
using the DAB substrate. Apoptosis was calculated as per-
centage of at least 1000 second cells. As shown in (Figure
7), treatment Ad/gTRAIL in meninglioma resulted in sig-
nificantly higher apoptotic 63.2% (C), when compared to
control Ad/CMV-GFP 4.4% (A). In glioma, treatment Ad/
gTRAIL resulted in higher apoptotic index 68.9% (D), com-
pared to Ad/CMV-GFP 5.2% (B). Result of in situ TUNEL
staining in tumor meningioma and glioma section.
β-actin
Meningioma Glioma
TRAIL
Meningioma Glioma
TRAIL
β-actin
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Treated with Ad/CMV -GFP 
Treated with Ad/gTRAIL 
Figure 5 The TRAIL gene expression in brain tumor cells: (A) Cells were treated with Ad/CMV-GFP at 1000 MOI VPs/ cell at 3 days. (B) Cells
were treated with Ad/gTRAIL at 1000 MOI VPs/ cell at 3 days. Protein levels were analyzed by Western blot analysis after the treatment. b-actin
was used as loading control.
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Figure 6 In vivo antitumor activity of Ad/gTRAIL: (A) Survival of animals treated with Ad/gTRAIL. Nude mice bearing intracranial M6 and U-87
xenografts were injected intratumorally with Ad/CMV-GFP or Ad/gTRAIL at doses of 1.5 × 10
8 viral particles in 5 μL for 3 days. The Kaplan-Meier
survival curve for each group was shown in the paragraph (n = 6 animals in each group). The mean survival for the control mice Ad/CMV-GFP)
was 19 days in M6 and 26 days in U87 respectively. In contrast, the survival for the Ad/gTRAIL treated mice was 61 days in M6 and 63 days in
U87, which was statistically significantly longer than the mean survival of control mice (p< 0.05). (B) The athymic mice brain section (B1) with
Meninglioma xenograft (B2).
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The tumor necrosis factor related apoptosis-inducing
ligand (TRAIL) has received a great attention in cancer
treatment because it induces apoptosis in cancer cells but
not in normal cells. TRAIL belongs to a small subset of
proapoptotic protein ligands in the TNF superfamily
[16,17], which triggers apoptosis through interactions
with death/TRAIL receptors (DR4/TRAIL-R1 and DR5/
TRAIL-R2)[18], and activation of caspase-8 at the death-
inducing signaling complex (DISC) on the cell surface
[19]. TRAIL-receptor agonists are considered as promis-
ing cancer therapeutics, and are currently under evalua-
tion in early clinical trials[20]. Recombinant human
Apo2L/TRAIL (rhApo2L/TRAIL), a dual proapoptotic
receptor agonist has been successfully studied in patients
with advanced cancer in clinical trial for cancer therapy
[20,21].
Our previous study showed that expression of TRAIL
in cancer cells induced apoptosis and bystander effect
a n dt h a tt h eb y s t a n d e re f f e c tr e q u i r e dc e l l - c e l lc o n t a c t
antitumor activity [22,23]. Required cell to cell contact
suggests that interaction of membrane TRAIL with its
receptors (DR5 or DR4) in neighboring cells is an impor-
tant mechanism of the TRAIL induced cell death. How-
ever, it remains unclear whether endogenous expression
of TRAIL itself will be sufficient to induce cell death. In
this study, we compared Ad/gTRAIL induced cell death
in relative confluent cells and in very diluted cultured
cells where cell-cell contact was minimal. Our result
showed that treatment with Ad/gTRAIL virus elicited
Meningioma tissue  Glioma tissue 
A B 
C D 
Figure 7 In vivo assess apoptosis by TUNEL assay:T i s s u es e c t i o no fm e n i n g i o m a( A ,C )a n dg l i o m a( B ,D )a t5 3d a y sa f t e rt r e a t m e n t .( A )
meningioma and (B) glioma treated with Ad/CMV-GFP. (C) meningioma and (D) glioma treated with Ad/gTRAIL. TUNEL staining was performed
as described in the Methods.
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Page 10 of 14similar levels of apoptosis in the confluent and diluted
cells, suggesting that endogenous expression of TRAIL
itself is sufficient to induce cell death in the sensitive can-
cer cells (data not shown).
Control of gene expression via tissue-or cell-specific
p r o m o t e r si sam e a n so ft a r g e t i n gt r a n s g e n ee x p r e s s i o n .
Tumor-specific promoters have the potential to selec-
tively destroy cancer cells while sparing normal cells. We
previously showed that hTERT promoter is highly active
in most cancer cells but not in normal cells and normal
mouse tissues, and can be used for targeting of the thera-
peutic effects of a proapoptotic gene using adenoviral
vector mediated gene delivery [12,24]. Nevertheless, com-
paring with a strong constitutive promoter such as CMV
promoter, the activity of hTERT is relatively weak.
Therefore, Ad/gTRAIL used bicistron expression system
to augment the hTERT promoter activity in cancer cells.
In this bicistron system, hTERT promoter is used to
drive the expression of GAL4/VP16 which in turn acti-
vates its target promoter consisting of GAL4 binding
sites and TATA box (GT)[25]. Targeted expression of
green Antitumor activity leading to augmented transgene
expression. Our previous study showed this system could
augment transgene expression from the CEA or hTERT
promoter up to 100 fold, whether in vitro or in vivo with-
out loss of its specificity [26,27].
Recombinant TRAIL proteins could elicit anticancer
activity without significant toxicity to most normal cells
[28]. Direct introduction of the TRAIL gene into cancer
cells elicited apoptosis and suppress tumor growth in vitro
and in vitro. A notable advantage of TRAIL gene therapy is
that TRAIL can kill nontransduced neighboring cancer
cells through bystander effects. TRAIL may become a ther-
apeutic agent for certain cancers. However, recent findings
that normal human hepatocytes, brain tissue, and certain
epithelial cells are susceptible to recombinant TRAIL pro-
teins[29], and that nonselective expression of TRAIL gene
in mice caused serious liver toxicity raised concerns about
the potential toxicity of systemically administration of
TRAIL. Targeting TRAIL gene expression to cancer cells
by hTERT is expected to improve the safety of TRAIL
gene therapy. Previous study showed that treatment of
some lung and colon cancer cells with Ad/gTRAIL elicited
strong antitumor activity in vitro and in vivo without toxic
effects on primary human hepatocytes and in mice [25]. In
breast cancer cells, Ad/gTRAIL was effective against cell
lines resistant to doxorubicin and soluble TRAIL protein.
Intralesional administration of Ad/gTRAIL effectively sup-
pressed xenografted tumor growth resulted in long-term
tumor-free survival in half of the mice [30]. This data sug-
gests that Ad/gTRAIL has potential application in cancer
therapy.
Meningiomas and gliomas are among the best candi-
dates for intralesional treatment with gene based agents
[31]. In addition, malignant gliomas and meningiomas
are predominantly telomerase positive, while normal
brain tissues are telomerase negative. Kondo and his col-
leagues made a couple of plasmid constructs in which
various caspases were put under the control of hTERT
promoter and they used these constructs for in vitro and
in vivo anti-glioma studies via liposome delivery system.
They showed that hTERT/caspase constructs induced
apoptosis in hTERT-positive malignant glioma cells but
not in astrocytes or fibroblasts in vitro [3,18]. Moreover,
these constructs significantly inhibited subcutaneously
established meningioma and glioma tumors in nude mice
by seven daily intratumoral injections. These studies pro-
vided the proof-of-principle evidence that hTERT pro-
moter-driven suicide therapy may become a novel
approach for the treatment of malignant meningiomas
and gliomas. Although in vitro and in vivo results are
encouraging, the potential use of these plasmid con-
structs in clinical settings is less promising. Compared
with other vector system, especially adenovirus, the
expression level mediated by liposome-DNA delivery is
significantly lower when intratumoral injection is per-
formed, whereas systemic treatment of malignant brain
tumor by gene therapy may not be possible clinically.
Adenovirus is the most widely used vector in cancer
gene therapy. Numerous clinical trials are based on adeno-
viral vector system [32,33]. We have made several adeno-
viral constructs using hTERT promoter to drive various
apoptotic genes. Ad/gTRAIL is one of these constructs. In
this study, we applied Ad/gTRAIL vector to glioma cells
with varying malignancies. We found that the response of
meningioma and glioma cells to Ad/gTRAIL treatment
correlate with their malignancy level. Those with high
malignancies are susceptible to Ad/gTRAIL treatment,
while benign lower grade glioma cells and benign menin-
gioma cells have very low hTERT expression and hence
low GFP-TRAIL expression. Ad/gTRAIL may become an
effective therapeutic agent for malignant brain tumors in
cases where surgery is not an option and even as a pro-
phylactic agent to prevent recurrence.
Methods
Primary cell culture and cell lines
Human tumor specimens were obtained and stored in
accordance with the human subject research protocols
approved by the institutional review board. The proces-
sing of tumor specimens has been described previously
[32,33]. Briefly, after resection, a portion of each tumor
was sent for routine histopathological analysis. The
remainder of all samples was immediately used to estab-
lish primary cultures. Tumor fragments were dispersed
into individual cells by treatment with Dispase 1 for 15 to
30 min at 37°C. From each tumor, 1 × 10
6 cells were then
plated in a 100 mm tissue culture dish in low-glucose
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fetal bovine serum (FBS), and 1% penicillin/streptomycin
mixture. The cells were grown to confluence and then
harvested, aliquoted, and stored in liquid nitrogen for
future use. The U251, U87, U373, and SW1088 glioma
cell lines were obtained from American Type Culture
Collection (Manassas, VA). The NG-1 glioma cell line
was a gift from Dr. TF Liu (University of Texas MD
Anderson Cancer Center). U251, U87, U373, SW1088
and NG-1 glioma cell lines were grown in DMEM high
glucose, L-glutamine medium with 10% FBS and 1%
penicillin/streptomycin mixture. All cells were cultured
in a humidified atmosphere containing 5% CO2 at 37°C.
Recombinant adenovirus vectors
Ad/gTRAIL were constructed as described previously
[34,35]. Ad/CMV-GFP was provided by Dr. T.J. Liu in our
institution. Virus titers were determined by optical absor-
bance at A260 and by plaque assay. Particle/plaque ratios
normally fell between 30:1 and 100:1. Based on a report by
others on evaluation of the concentration [36], and our
own experience, vector titers determined by A260 were
used in this study while titers determined by plaque assays
were used as additive information. Thus, the multiplicity
of infection (MOI) of 1000 VPs was equivalent to an MOI
of 10-30 infectious units. Unless otherwise specified, Ad/
CMV-GFP was used as the vector control, and PBS was
used as a mock control. All viral preparations were free of
contamination by E1
+ adenovirus and endotoxin.
Adenovirus infection
For the infectivity analyses, human benign and malignant
tumor cells (5 × 10
5 ) were infected with 1000 MOI Ad/
g-TRAIL, 1000 MOI Ad/CMV-GFP, or PBS, in which
Ad/g-TRAIL, Ad/CMV-GFP-infected cells express GFP.
72 hours after infection, the cells were treated with 0.05%
trypsin for 5 minutes and washed twice with phosphate-
buffered saline (PBS). The cells were then counted for
GFP-positive cells by flow cytometry as described below,
or visualized and photographed by using a Nikon Eclipse
TE300 inverted fluorescence microscope (Nikon, Mel-
ville, NY) and were analyzed with MetaMorph imaging
software (Universal Imaging Corp Downington, PA).
Cell viability assay
Human benign and malignant tumor cells were seeded in
at a density of 3 × 10
3 cells/well in 96 well plates and
allowed to grow for 20 hours at 37°C. Cells were then
infected with 1000 MOI Ad/g-TRAIL, 1000 MOI Ad/
CMV-GFP, or PBS at 7 days respectively. Cell viability was
determined by 3-bis-[2-methoxy-4-nitro-5 sulfenyl]-2H-
tetrazolium-5-carboxanilide inner salt (XTT) assay (Cell
Proliferation Kit II; Roche Molecular Biochemicals, India-
napolis, IN) following manafacturer’s instructions. Each
experiment was performed in quadruplicate and repeated
at least three times.
Real-time quantitative RT-PCR
Total RNA was extracted using the Mini-prep RNeasy kit
(Qiagen). cDNA synthesis was constructed from high-
grade RNA from all samples using the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems, Fos-
ter City, CA, USA). Real-time Q PCR was performed in
the ABI Prism 7700 Sequence Detection System according
to the protocol of the manufacture. Typical amplification
mixes (25μl) contained the sample DNA (or cDNA), 10×
TaqMan Buffer (2.5μl), 200μmd A T P ,d c P ,d G T P ,a n d
400μMd U T P ,5m MM g C l 2,0 . 6 5u n i t so fA m p l iT a q
Gold, 0.25 units of AmpErase uracil N-glycosyladse
(UNG), 200 nM each primer and 100 nM probe. The ther-
mal cycling conditions consist of 1 cycle at 2 min for 50°C
and 10 min for 95°C, and 50 cycles of 95°C 15 s and 60°C
for 1 min. All reactions were performed in duplicates.
After the reaction, we used the built-in software in the
7700 system to perform analyses of the data and generate
the standard curve, the Ct value of each testing sample
and their corresponding starting quantity based on the
relative standard curve.
Western blot analysis
The cells treated with 1000 MOI Ad/CMV-GFP or
1000 MOI Ad/g TAIL at 3 days, the cell protein
extraction was performed with Laemmli lysis buffer.
Equal amounts of lysate were separated using 10%
SDS-PAGE and transferred to Hybond enhanced che-
miluminescence membranes (Amersham, Piscataway,
NJ). The membranes were blocked with PBS-T con-
taining 5% non-fat milk for 1 h or overnight at 4°C,
and incubated with primary antibodies for 1 h at room
temperature. After washing three times with PBS con-
taining 0.05% Tween, the membranes were incubated
with peroxidase-conjugated secondary antibodies and
developed using a chemiluminescence detection kit
(ECL kit; Amersham).
Fluorescence-activated cell sorting (FACS) and flow
cytometric analysis
Cells were seeded at 1 × 10
5/well in 6-well plates, and
after an overnight incubation, cells were either treated
with 1000 MOI Ad/CMV-GFP or Ad/gTRAIL or com-
plete media (control cells) for 24 hours. 72 hours later,
both adherent and floating cells were harvested by tryp-
sinization, washed with PBS, and fixed in 70% ethanol
overnight at 4°C. Before analysis, cells were stained with
propidium iodide for 30 min. The apoptosis induction
was quantified by flow cytometric analysis. All experi-
ments were performed in the Core Laboratory of the
M. D. Anderson Cancer Center.
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Animals
Protocol for animal use was approved by the Institu-
tional Animal Care and Use Committee of Baylor Col-
lege of Medicine, and was in accordance with National
Institutes of Health guidelines (NIH publication number
85-23).
Procedure
A total of 24 female, 10-weeks-old, nu/nu athymic mice
(Charles River Lab) were used. Human meningioma M6
and glioma U87 cell lines (at a concentration of 1 × 10
6
cells/5 μL) were resuspended in PBS and injected into
t h er i g h tf r o n t a ll o b eo fn u d em i c eu s i n gag u i d e - s c r e w
system implanted within the skull as described previous
[21,37,38]. On day 3, after the implantation of tumor
cells, animals were divided into four groups, and the
each group is treated with one single intratumoral injec-
tion (1.5 × 10
8 viral particles in 5 μL) with following:
the first group animals (n = 6) were treated with Vec-
tors Ad/CMV-GFP for meni n g i o m aM 6 ;t h es e c o n d
group animals (n = 6) were treated Vectors Ad/gTRAIL
for meningioma M6; the third group animals (n = 6)
were treated with Vectors Ad/CMV-GFP for glioma
U87; the fourth group animals (n = 6) were treated with
Ad/gTRAIL for glioma U87. Mice were anesthetized
with xylazine/ketamine during the procedure. Mice
showing general or local symptoms of toxicity were
killed. When the animals became moribund due to
tumor progression, they were euthanized and the brains
were removed, fixed in 4% formaldehyde for 24 h at
room temperature
Histology and tumor analysis
Brain tissue fixed for 24 h in 10% formalin solution,
transferred to a 70% ethanol solution, and processed for
paraffin embedding. Serial sections (6 μm) were pre-
pared and stained with H&E according to standard his-
topathologic techniques. Stained sections were examined
under light microscope (×100 magnification).
Apoptosis assay
To detect apoptotic cells in tumor, we used an in situ cell
death detection kit, POD (Roche Applied Science, India-
napolis, IN). The staining was performed according to
the manufacturer’s instructions, counterstained with hae-
matoxylin, and viewed under a light microscope (×400
magnification). Brown staining indicates oligonucleosome
cytoplasmic release resulting from apoptosis-induced
DNA fragmentation. Counting was performed in ran-
domly chosen fields, and the apoptosis was calculated as
a percentage of at least 1,000 scored cells. Data analyzed
with ImageJ software. Images segmented and the number
of apoptotic cells quantified.
The standard fluorescein isothiocyanate-dependent
apoptosis assay techniques (TUNEL or Annexin V)
could not be used in this study because Ad/gTRAIL-
infected cells express GFP, which interferes with fluor-
escein isothiocyanate detection by means of flow
cytometry.
Statistical analysis
Differences among the experimental groups were ana-
lyzed by analysis of variance (AOV) using statistical soft-
ware (StatSoft, Tulsa, OK). A difference was considered
statistically significant when the P value was 0.05 or less.
Differences in tumor growth in vivo among the treat-
ment groups were assessed by AOV with a repeated
measurement module. AOV was performed to deter-
mine statistical significance between each treatment
group by using the SAS procedure with the SAS version
6.12 software. Survival was assessed by using the
Kaplan-Meier method. Survival in different treatment
groups was compared using the log-rank test.
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